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INTRODUCTION 
 4 
Restless legs syndrome (RLS) is the most common disorder of movement 
and quiet wakefulness, with a prevalence in the general population of 10–
12% (with a range of 5–20% among different studies), that increases with 
age and is higher in women than in men (Trenkwalder C et al, 2005; Allen 
RP et al, 2003). It is characterised by an irresistible urge to move the legs, 
associated with unpleasant paraesthesias in the legs and sometimes in the 
arms. These sensations occur at rest, in particular in the evening or at night, 
and are relieved by movement. Many patients also have periodic limb 
movements in sleep (PLMS) and wakefulness (PLMW) and they may 
complain of insomnia and/or hypersomnia (Trenkwalder C et al, 2005; 
Allen RP et al, 2003). In the 70-80% of cases it is an idiopathic disorder 
with no apparent cause and in the remaining part is described as a 
symptomatic syndrome associated with pregnancy, uremia, iron depletion, 
polyneuropathy, spinal disorders, and rheumatoid arthritis (Bassetti C et al, 
2001, Trenkwalder C et al, 2005), which is probably more correct to 
consider “risk factors” (Zucconi M, Ferini-Strambi L, 2004). 
 
Historical note 
 
The first clinical description of restless legs is attributed to Thomas Willis, 
which described the syndrome in 1672 (Willis, 1685). In 1861 Wittmaack 
called the disorder "anxiety tibiarum," and wrote that it was a frequent 
symptom of hysteria (Wittmaack, 1861). Oppenheim was the first to define 
the disease as a neurologic illness and the first to recognize the genetic 
component of the disease (Oppenheim, 1923). The first significant clinical 
review of restless legs syndrome was written by Ekbom in 1945. He 
provided the basic modern description of the disorder and first suggested the 
currently accepted term “restless legs syndrome”. His monograph described 
2 forms of the disorder: one form presents with prominent paresthesia, 
"asthenia crurum paresthetica," and the other form presents with prominent 
pain, "asthenia crurum dolorosa" (Ekbom, 1945). In 1953 Nils-Brage 
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Nordlander was the first to propose that iron deficiency may play a primary 
role in restless legs syndrome (RLS) (Nordlander NB, 1953). In 1953 
Symonds described 5 patients with jerking of the extremities during sleep. 
He thought it could represent an epileptic disorder and called it "nocturnal 
myoclonus" (Symonds CP et al, 1953). In 1965, Lugaresi and colleagues 
first videopolysomnographically documented the presence of PLMS 
(adopting the Symonds’ definition) in patients with RLS (Lugaresi E et al, 
1965). 
 
Clinical features and diagnosis 
 
In 1995, clinical diagnostic criteria for the restless legs syndrome were 
established by the International Restless Legs Syndrome Study Group 
(IRLSSG) (Walters AS, 1995), and reviewed in 2003 (Allen RP et al, 2003). 
These include four essential criteria that all must be met and three 
supportive criteria. Furthermore additional significant clinical features are 
associated with the disorder. 
 
Essential diagnostic criteria for RLS 
1) An urge to move the legs, usually accompanied or caused by 
uncomfortable and unpleasant sensations in the legs (Sometimes the 
urge to move is present without the uncomfortable sensations and 
sometimes the arms or other body parts are involved in addition to 
the legs) 
2) The urge to move or unpleasant sensations begin or worsen during 
periods of rest or inactivity such as lying or sitting 
3) The urge to move or unpleasant sensations are partially or totally 
relieved by movement, such as walking or stretching, at least as long 
as the activity continues 
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4) The urge to move or unpleasant sensations are worse in the evening 
or night than during the day or only occur in the evening or night 
(When symptoms are very severe, the worsening at night may not be 
noticeable but must have been previously present) 
 
Supportive clinical features of RLS 
1) Family history: he prevalence of RLS among first-degree relatives of 
people with RLS is 3 to 5 times greater than in people without RLS. 
2) Response to dopaminergic therapy: nearly all people with RLS show 
at least an initial positive therapeutic response to either L-dopa or a 
dopamine-receptor agonist at doses considered to be very low in 
relation to the traditional doses of these medications used for the 
treatment of Parkinson disease. This initial response is not, however, 
universally maintained. 
3) Periodic limb movements (during wakefulness or sleep): periodic 
limb movements in sleep (PLMS) occur in at least 85% of people 
with RLS; however, PLMS also commonly occur in other disorders 
and in the elderly. In children, PLMS are much less common than in 
adults. 
 
Associated features of RLS 
1) Natural clinical course: the clinical course of the disorder varies 
considerably, but certain patterns have been identified that may be 
helpful to the experienced clinician. When the age of onset of RLS 
symptoms is less than 50 years, the onset is often more insidious; 
when the age of onset is greater than 50 years, the symptoms often 
occur more abruptly and more severely. In some patients, RLS can 
be intermittent and may spontaneously remit for many years. 
2) Sleep disturbance: disturbed sleep is a common major morbidity for 
RLS and deserves special consideration in planning treatment. This 
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morbidity is often the primary reason the patient seeks medical 
attention. 
3) Medical evaluation/physical examination: the physical examination 
is generally normal and does not contribute to the diagnosis except 
for those conditions that may be comorbid or secondary causes of 
RLS. Iron status, in particular, should be evaluated because 
decreased iron stores are a significant potential risk factor that can be 
treated. The presence of peripheral neuropathy and radiculopathy 
should also be determined because these conditions have a possible, 
although uncertain, association and may require different treatment. 
 
In summary RLS is a sensorimotor disorder. The sensory components 
include discomfort in the legs with an urge to move that patients report 
using different and sometimes bizarre descriptions: creepy-crawly, ants 
crawling, jittery, pulling, worms moving, soda bubbling in the veins, electric 
current, shock-like feelings, pain, the gotta moves, burning, jimmy legs, 
heebie jeebies, tearing, throbbing, tight feeling, grabbing sensation, elvis 
legs, itching bones, crazy legs, fidgets (Walters AS, 1996). The motor 
component is characterized by the need to walk and involuntary periodic leg 
movements during wakefulness (PLMW) and during sleep (PLMS).  
In the diagnostic process particular attention must be made in order to 
exclude other conditions that may resemble RLS. Indeed, an interview with 
a trained physician is necessary for the correct diagnosis of RLS: if only 
questionnaires with the RLS criteria are given to patients this results in 
approximately 10–25 % false positives due to the so-called “RLS mimics”, 
which include akathisia, nocturnal leg cramps, peripheral neuropathy, 
lumbosacral radiculopathy, painful legs and moving toes, growing pains, 
attention deficit hyperactivity disorder (ADHD) (Hening WA et al, 2009). 
Useful diagnostic tool is the suggested immobilization test (SIT), that 
evaluates periodic leg movements (PLM) and self-reported sensory 
symptoms for people who are instructed to remain still for 1 h while sitting 
on a bed with their legs outstretched (Michaud M et al, 2002). 
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Polysomnography allows accurate assessment of PLMS, scoring them only 
if they occur in a series of four consecutive movements lasting 0.5-5 s, have 
an amplitude of one quarter or more of the toe dorsiflexion during 
calibration and are separated by intervals of 4-90 s. They occur during the 
stages 1-2 of NREM sleep, diminish during stages 3-4 and nearly always 
disappear during REM sleep. An index (number of PLMS per hours of 
sleep) greater than 5 for the entire night is considered pathologic and is 
supportive, although not specific, of the diagnosis of RLS (Zucconi M et al, 
2006). The PLMW, both during the sleep period and the SIT, appear to be 
more specific for RLS, but the data for this finding remain limited 
(Montplaisir J, et al, 1998; Nicolas A et al, 1999).  
With regard to the quantification of RLS symptoms, since it is primarily a 
subjective disorder, a subjective scale represents the optimal instrument to 
measure disease severity for clinical assessment, research, or therapeutic 
trials. Therefore, in 2003 the IRLSSG proposed and validated a rating scale, 
consists of ten questions, whose total score progresses from 0 to 40 with the 
degree of disease severity (Walters AS et al, 2003). 
 
Genetics 
A family history of RLS is present in more than 50% of affected individuals 
(Zucconi M, Ferini-Strambi L, 2004).  RLS is 3-5 times greater amongst 
first degree relatives of subjects suffering from RLS than in subjects without 
RLS (Allen RP et al, 2003) and pedigrees mostly suggest an autosomal-
dominant transmission with high penetrance. The possibility of anticipation 
has been described (Trenkwalder C et al, 1996; Lazzarini A et al, 1999). 
Variations in penetrance and anticipation suggest possible genetic 
heterogeneity (Lazzarini A et al, 1999). RLS has also been reported to have 
a high concordance for monozygotic (61%) and dyzygotic twins (45%) 
(Desai AV et al, 2004). Clinically, familial forms cannot be differentiated 
from sporadic or symptomatic forms (Winkelmann J et al, 2000) except for 
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an earlier age of onset and a more slowly progressive course in familial 
cases (Allen RP and Earley CJ, 2000;  Winkelmann J et al,  2002). 
Linkage analysis actually have detected nine gene loci associated to familial 
forms of RLS (RLS1-9), located on chromosomes 12q, 14q, 9q, 2q, 20p, 4q, 
17p, 19p, 16p, all autosomal-dominant except the first one that is recessive 
(Trenkwalder C et al, 2009; Levchenko A et al, 2009), but no candidate 
gene has been identified.  On the basis of knowledge of the pathophysiology 
of RLS (see below) some candidate genes have been studied - i.e. those 
coding for D1–D5 receptors, DAT, TH, Dopamine β hydroxylase, GTP 
cyclohydrolase, GABA A receptor subunits (α1-6, β 1-3, χ1-3, p1-2), α-1 
subunit of the glycine receptor (chromosome 5q31), MAO-A, MAO-B, 
Neurotensin – without disclosing any mutation or clearly predisposing 
polymorphism (Winkelmann J et al,  2007a; Dhawan V et al, 2006).  
Recently, a genome-wide case-control study of single-nucleotide-
polymorphisms (SNPs) has showed association between RLS and three 
genetic loci: one within MEIS1, one within BTBD9 and one between 
MAP2K5 and LBXCOR1 (Winkelmann J et al, 2007b). Another genome-
wide association study of RLS and PLM reported association with one of 
these genes, BTBD9 (Stefansson H et al, 2007). All these genes have been 
implicated in development mechanisms, raising the possibility that RLS has 
components of a developmental disorder.  Interestingly BTBD9 also affects 
ferritin level and iron storage (Mignot E, 2007). 
 
Pathophysiology 
 
The pathophysiology of RLS is poorly understood. A lot of observations 
point towards an involvement of central nervous structures and networks, 
dopaminergic system and iron metabolism. 
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Central nervous structures and networks 
RLS dysfunction appears to involve the central nervous system, but the 
areas involved are somewhat uncertain. Functional MRI (fMRI) 
demonstrated an activation of the thalamus (legs discomfort), cerebellum 
(legs discomfort and PLM), red nuclei and brainstem (PLM) (Bucher SF et 
al, 1997). A more recent fMRI study, using only a motor paradigm, found 
activation in the thalamus, the putamen, the middle frontal gyrus and the 
cingulated gyrus (Astrakas LG et al, 2008). 
Electrophysiological studies suggest that the movements are involuntary and 
are organized at the brainstem or spinal level (Trenkwalder C et la, 1996). 
Patients with periodic leg movements of sleep, with or without associated 
restless legs syndrome, may have abnormal blink reflexes (Briellmann RS et 
al, 1996). H-reflexes with its modulation (Martinelli p and Coccagna G, 
1976; Rijsman RM et al, 2005; Scaglione et al 2008) and flexor reflex 
(Bara-Jimenez W et al, 2000) are impaired suggesting a brainstem or more 
rostral dysfunction leading to enhanced spinal excitability. Cortical 
prepotentials associated with the PLMS or PLMW have generally not been 
found (Lugaresi et al, 1986; Trenkwalder et al, 1993). Recently a study 
disclosed that in RLS patients the event-related beta and mu 
(de)synchronization amplitudes and durations for voluntary movement were 
greater during the symptomatic period (at 8:30 PM) than during the 
asymptomatic (at 8:30 AM) period and in comparison with healthy controls, 
suggesting the presence of cortical sensorimotor dysfunction (Tyvaert L et 
al, 2009a). Cortical transcranial magnetic stimulation (TMS) studies in RLS 
show that the pyramidal tract is intact, whereas the excitatory and inhibitory 
system seems to be altered, but can be influenced and restored by treatment 
with dopamine-agonists (Nardone R et al, 2006; Kutukcu Y et al, 2006; 
Gorsler and Liepert, 2007; Rizzo V et al, 2009).  
All these studies are consistent with a subcortical dysfunction that alters 
function of the motor pathways. 
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Clinical observations in patients after an ischemic stroke suggest that lesions 
of the subcortical brain areas such as the pyramidal tract, thalamus and the 
basal ganglia-brainstem axis, which are involved in motor functions and 
sleep-wake cycles, may lead to RLS symptoms (Lee SJ et al, 2009; Unrath 
A et al, 2006). A study in patients with multiple sclerosis disclosed a higher 
prevalence of RLS associated to greater cervical cord damage and 
speculated about a possible brain-spinal disconnection (Manconi M et al, 
2008). 
Therefore, RLS appears as a complex movement disorder affecting several 
levels of the neuraxis, even though the precise pathoanatomic location of 
this dysfunction has not yet been determined (Barrière G et al, 2005). 
However, there is evidence for impairment of sensorimotor processing at the 
level of the cortex and the spinal cord, suggesting altered 
subcortical/supraspinal control. 
 
Structural and microstructural abnormalities in MR studies 
Conventional cranial MRI does not identify any structural abnormalities in 
RLS patients. MR studies using advanced techniques reported contrasting 
data. A voxel based morphometry (VBM) study detected a bilateral gray 
matter increase in the pulvinar and the authors assumed that these changes 
in thalamic structures may reflect a consequence of chronic increase in 
afferent input of behaviourally relevant information (Etgen T et al, 2005). 
Successive VBM studies did not confirm this result, but one disclosed 
significant regional decreases of gray matter volume in the bihemispheric 
primary somatosensory cortex, which additionally extended into left-sided 
primary motor areas (Unrath A et al, 2007), another one slightly increased 
gray matter density in the ventral hippocampus and in the middle 
orbitofrontal gyrus (Hornyak M et al, 2007), and yet another one lack of 
specific gray matter alterations (Celle S et al, 2009). 
Only one diffusion tensor imaging (DTI) study of RLS is present in 
literature (Unrath A et al, 2008). In the patient group, multiple subcortical 
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areas of significantly reduced fractional anisotropy (FA) (a quantitative 
marker of white matter integrity) were observed bihemispherically in close 
proximity to the primary and associate motor and somatosensory cortices, in 
the right-hemispheric thalamus (posterior ventral lateral nucleus), in motor 
projectional fibers and adjacent to the left anterior cingulum. The authors 
suggested that these findings gave support to an altered subcortical network, 
with the major component of altered cerebral sensorimotor pathways, within 
a hodological concept of the RLS pathoanatomy (Unrath A et al, 2008). 
Despite these conflicting data the investigation about structural 
abnormalities in RLS remains an actual point of interest, also in light of the 
discovery of a possible role of genes involved in development mechanisms 
(MEIS1, BTBD9, MAP2K5 and LBXCOR1) (Winkelmann J et al,  2007b). 
 
Dopaminergic system 
The dopaminergic system involvement is highly probable because treatment 
with dopamine agonists shows efficacy as confirmed by controlled trials, 
while dopamine antagonists worsen symptoms or may even elecit RLS 
(Barrière G et al, 2005). Many studies reported an increased prevalence of 
RLS in PD patients, although they are difficult to interpret because the 
current diagnostic criteria for RLS have not been validated in PD patients 
and “RLS mimics” could have been affect the results (Möller JC et al, 
2010). PET and SPECT studies revealed some controversial results of the 
pre- and postsynaptic dopaminergic neurotrasmission system. Almost all 
have focused on the striatum, a brain region receiving dense dopaminergic 
innervations, showing slight reduction binding or no difference of both 
presynaptic ([123I]βCIT, [123I]IPT or [99mTc]TRODAT-1 in SPECT studies 
and 18F-dopa in PET studies) and postsynaptic D2 radioligand ([123I]IBZM 
in SPECT studies and 11C-raclopride in PET studies) in RLS patients when 
compared with control subjects (Wetter TC et al, 2004; Hilker R et al, 
2006). Taken together, these results suggest that at level of nigro-striatal 
pathway the membrane dopamine transporter and postsynaptic D2-receptor 
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seem to be either unchanged or mildly reduced in patients with idiopathic 
RLS. The most recent PET study investigated, besides striatal regions by 
11C-raclopride, other extrastriatal dopaminergic regions by FLB 457 (a new 
postsynaptic high-affinity D2 radioligand) and disclosed a higher binding 
potential in patients than controls at level of limbic and associative part of 
striatum,  medial and posterior part of thalamus, anterior cingulate cortex 
and insule, all part of the medial nociceptive system which is thought to 
regulate the affective-motivational component of pain. The authors 
sustained the hypothesis of hypoactive dopaminergic neurotrasmission 
associated to receptor up-regulations (Cervenka S et al, 2006). An 
involvement of the medial nociceptive system was supported also by a PET 
with [11C]diprenorphine, a non-selective opioid receptor radioligand, which 
found regional negative correlations between ligand binding and RLS 
severity in areas serving the medial pain system (medial thalamus, 
amygdala, caudate nucleus, anterior cingulate gyrus, insular cortex and 
orbitofrontal cortex) (von Spiczak S et al, 2005). 
In a recent pathological study, the substantia nigra and putamen were 
obtained at autopsy from individuals with primary RLS and a neurologically 
normal control group and a quantitative profile of the dopaminergic system 
was obtained. RLS tissue, compared with controls, showed a significant 
decrease in D2R in the putamen that correlated with severity of the RLS. 
RLS also showed significant increases in tyrosine hydroxylase (TH) in the 
substantia nigra, compared with the controls but not in the putamen, and 
both with the decrease of D2R, interpreted as a down-regulation, led authors 
to hypothesize an overly activated dopaminergic system as possible part of 
the RLS pathology (Connor JR et al, 2009). The hypothesis of an increase in 
dopamine activity and turnover is consistent with the recent CSF studies 
showing increased 3-Ortho-methyldopa (3OMD) in RLS patients off 
dopamine treatment that correlates well with increased HVA (Allen et al, 
2008). 
These contrasting data could be explained by the difference in the 
methodologies and in selected patients (mild o severe RLS). However, even 
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if cerebral metabolism in RLS probably reflects a dysfunction of the central 
dopaminergic system, it has still to be determined whether these alterations 
affect mainly the nigrostriatal and/or other central dopaminergic systems 
like the diencephalospinal or mesolimbic pathway and whether they are the 
primary mechanisms or only secondary phenomena within the manifestation 
of RLS symptoms.   
In the last years great interest has developed around the involvement of 
diencephalospinal pathway in RLS. Some authors forward the hypothesis 
that RLS reflects a dysfunction of the little-studied dorso-posterior 
hypothalamic dopaminergic A11 cell group (Clemens S et al, 2006). The 
A11 cell group in the dorso-posterior hypothalamus and subparafascicular 
thalamus is the largest, possible sole, source of spinal DA (Skagerberg G et 
al, 1982 and 1985; Qu S et al, 2006). A11 spinal projections innervate all of 
Rexed’s laminae and are most heavily concentrated in the superficial 
sensory-related dorsal horn and the intermediolateral nucleus (IML). They 
modulate sensory inputs and sympathetic drive, predominantly with 
inhibitory action through D2 and especially D3 receptors (Clemens S et al, 
2006). This theory was supported from some animal models which 
disclosed that D3 receptor knockout (D3KO) mice are hyperactive and 
manifest an increased wakefulness across the rest-activity cycle (Accili D et 
al, 1996; Hue GE et al, 2003) and that locomotor activities were 
significantly increased in A11-lesioned mice compared with controls (Ondo 
WG et al, 2000; Qu S et al, 2007). A recent neuropathological study shows 
no evidence of changes in the number and volume of TH (+) neurons, 
neither atrophy nor hypertrophy nor gliosis in the A11 region in the 
posterior hypothalamus of RLS patients compared with age-matched control 
cases (Earley CJ et al, 2009). These results could support a functional 
involvement rather than a degeneration of A11 region.  
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Iron metabolism 
The potential central role of iron metabolism involvement in RLS is 
indicated primarily by those secondary forms of RLS in which iron 
insufficiency is clear, but also from some limited pharmacological studies 
which demonstrated that by using intravenous or oral iron, one could 
markedly improve, if not resolve, RLS symptoms, even in those who 
apparently had normal blood levels of iron (Nordlander NB, 1953; Earley 
CJ et al, 2005; Wang J et al, 2009). Several studies showed a relation 
between low ferritin concentrations and symptoms of the syndrome, 
especially when ferritin was measured in the cerebrospinal fluid (CSF). This 
link to the iron deficiency is particularly strong for early-onset RLS (Clardy 
SL et al, 2006a). Studies on CSF showed decreased ferritin, elevated 
transferrin and decreased pro-hepcidin (that interacts with the iron transport 
protein ferroportin on the surface of cells) in patients with RLS (Clardy SL 
et al, 2006b). Neuropathological studies found alterations of iron regulatory 
proteins (decreased ferritin, divalent metal transporter 1, ferroportin, 
transferrin receptor and increased hepcidin) in neuromelanin cells from 
brains of patients (Connor JR et al, 2003 and 2004). Altered iron 
metabolism was disclosed in lymphocytes from subjects with RLS (Earley 
CJ et al, 2008). A recent pathological study showed that RLS substantia 
nigra had more mitochondrial ferritin levels and less cytosolic H-ferritin 
than control samples (Snyder AM et al, 2009). Reduced brain iron in RLS 
patients is also suggested by the data of some MR studies that exploit the 
effect of iron on T2, T2* and T2' (and associate parameters R2, R2* and 
R2'), although with discrepant results. It has been well documented through 
in vitro studies that paramagnetic iron will increase proportionally proton 
transverse relaxation rates (R2=1/T2). Furthermore, ferritin and hemosiderin 
are considered to be the only forms of nonheme iron present in sufficient 
quantities to affect MR contrast in the human brain (Haacke EM et al, 
2005).  In two studies of the same group regional brain iron concentration 
were assessed in RLS patients by R2' measurement, and the mean iron 
content from the substantia nigra was significantly lower in the early-onset 
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RLS patients (< 45 years) and not in the late-onset (Allen RP et al, 2001; 
Earley CJ et al, 2006). In a study performed in patients with late-onset RLS, 
the T2 relaxation time was assessed separately for the two components of 
the SN, and low iron content was found in the SN pars compacta (and not in 
the pars reticolata) (Astrakas LG et al, 2008). Another group, without 
differentiating between early-onset and late-onset, disclosed that mean T2 
values of multiple regions were higher in RLS patients, though significantly 
increased only in four regions (caudate head, thalamus medial, dorsal and 
ventral); the mean T2 over all voxels was higher in patients, indicating a 
multiregional (global) brain iron deficiency in RLS patients (Godau J et al, 
2008). Also transcranial B-Mode sonography was used in RLS patients 
which exhibited substantia nigra hypoechogenicity correlated inversely with 
T2 values and interpreted as related to iron deficiency (Schmidauer C et al, 
2005; Godau J et al, 2008). 
These observations has led to a more general iron-dopamine model of RLS 
and it has been suggested that dopaminergic dysfunction can be mediated by 
low brain iron levels since iron is needed as a cofactor for tyrosine 
hydroxylase (the rate limiting enzyme in the synthesis of dopamine), 
because the D2 receptor is a protein containing iron, and because the 
dopaminergic synaptic protein Thy-1 requires iron for its activity. Hence a 
brain iron deficiency could lead to lowering dopamine production via 
reduced tyrosine hydroxylase activity, down-regulation of dopamine type 2 
receptors and destabilization of dopaminergic synapses (Allen RP, 2004; 
Allen RP and Earley CJ, 2007). 
In support of this hypothesis there are some animal models which reported 
increase of wakefulness in the 4 hours preceding the resting phase of iron-
deficient mice (Dean T et al, 2006), increased locomotor activities in the 
mice that were iron deprived, with a further significantly augmented activity 
after combination of iron deprivation and A11 lesions (Qu S et al, 2007), 
increased locomotor activities in the mice treated with iron-deficiency diet 
(ID), which were reversed by the D2/D3 agonist ropinirole, and a 
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synergistic greater decrease of spinal cord D2 binding in mice underwent 
both ID and 6-OHDA lesion of A11 region (Zhao H et al, 2007). 
Finally BTBD9 gene recently associated to RLS and PLM, affects ferritin 
level and iron storage (Winkelmann J et al, 2007b; Stefansson H et al, 2007; 
Mignot E, 2007). 
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OBJECTIVES 
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This study was designed to evaluate RLS patients by multiple advanced MR 
techniques in order to investigate three different aspects of the 
pathophysiology of the disease: 
1) To evaluate the presence of structural and/or microstructural 
abnormalities in the brain of RLS patients using voxel-based 
morphometry (VBM) and diffusion tensor imaging (DTI) analysis, 
considering the contradictory data reported in previous studies 
(Etgen T et al, 2005; Hornyak M et al, 2007; Celle S et al, 2009; 
Unrath A et al, 2007 and 2008). 
2) To investigate metabolic functions of the thalamus of RLS patients 
using proton magnetic resonance spectroscopy (1H-MRS), 
considering the possible involvement of this structure disclosed by 
MRI (Bucher SF et al, 1997; Astrakas LG et al, 2008; Lee SJ et al, 
2009; Unrath A et al, 2006) and PET studies (Cervenka S et al, 
2006; von Spiczak S et al, 2005). 
3) To evaluate brain iron content in RLS patients using phase imaging. 
The primary hypothesis was that patients have low whole-brain iron 
levels. Additionally certain regions previously suspected of low 
iron concentrations were assessed separately (Allen RP et al, 2001; 
Earley CJ et al, 2006; Astrakas LG et al, 2008; Godau J et al, 
2008). 
VBM 
VBM is an automated technique that assesses patterns of regional atrophy 
on MRI between groups of subjects. Mainly and more accurately it 
investigates voxel-wise changes in the grey matter volume/topography 
rather than white matter. The procedure is relatively straightforward and 
involves spatially normalizing high-resolution images from all the subjects 
in the study into the same stereotactic space. This is followed by segmenting 
the gray matter from the spatially normalized images and smoothing the 
gray-matter segments. Voxel-wise parametric statistical tests which 
compare the smoothed gray-matter images from the groups are performed. 
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Corrections for multiple comparisons are made using the theory of Gaussian 
random fields (Ashburner J and Friston K, 2000). It is unbiased in that it 
looks throughout the whole brain and does not require any a priori 
assumptions concerning which structures to assess. This gives it a 
significant advantage over more traditional region of interest (ROI) based 
methods, which typically involve drawing around a structure of interest.  
DTI 
Diffusion tensor imaging (DTI) is sensitive to water diffusion characteristics 
(such as the principal diffusion direction and the diffusion anisotropy) and 
has therefore been developed as a tool for investigating the local properties 
and integrity of brain tissues, mainly at level of white matter tracts but also 
at level of grey matter (Pierpaoli P et al, 1996). Post-processing of the 
acquisitions allows the reconstruction of maps of the mean diffusivity (MD) 
and of the white matter anisotropic properties, usually in terms of fractional 
anisotropy (FA) (Mascalchi M et al, 2005). Neuronal and/or axonal loss is 
typically characterised by increased MD and reduced FA, as modification of 
brain tissue integrity reduces the barriers that restrict the movement of water 
(Rizzo G et al, 2008; Agosta F et al, 2009). Maps of MD and FA may be 
analysed using a ROIs approach to evaluate single structures, using a 
histogram approach to evaluate greater portions of the brain or whole brain 
and using voxel-wise analyses for an unbiased approach. We utilised all 
three approaches. For the voxel-wise analyses we used tract-based spatial 
statistics (TBSS), which aims to solve crucial issues of cross-subject data 
alignment, allowing localized cross-subject statistical analysis (avoiding the 
arbitrariness of the choice of spatial smoothing extent), using the ‘‘mean FA 
skeleton’’ approach (Smith SM et al, 2006 and 2007). 
1H-MRS 
Magnetic resonance spectroscopy (MRS) is a noninvasive method that 
permits measurement of the concentration of specific biochemical 
compounds in the brain and other organ systems in precisely defined regions 
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guided by MR imaging. With MR spectroscopy we can measure spectra of 
many biologically interesting isotopes. In vivo biomedical applications are 
mainly focused on proton (1H), phosphorus (31P) and carbon (13C) isotopes 
(Hajek M et al, 2008). The most used in clinical practice is 1H MRS. At 
long echo-time (TE) 1H MRS can detect N-acetyl-aspartate containing 
compounds, choline containing compounds, creatine-phosphocreatine and 
lactate. At short TE, lipids, tryglicerides, glutamate, glutamine, scyllo-
inositol, glucose, myo-inositol, are visible (Bonavita S et al, 1999). The 
most relevant metabolites in neurological studies are probably N-acetyl-
aspartate (NAA), a neuronal marker (Kantarci K et al, 2008), and myo-
inositol (mI) a glial marker (Brand A et al, 1993). 1H MRS can be 
performed with single-voxel, multivoxel, single slice and multislice 
techniques. This technique can be useful in the study a number of central 
nervous system disorders such as epilepsy, brain tumors, stroke, multiple 
sclerosis, degenerative disorders (identification of microscopic pathology 
not visible with MRI) and metabolic diseases (metabolic disturbances with 
specific metabolic patterns) (Lodi R et al, 2009; Bonavita S et al, 1999).  
Phase imaging 
This is a new neuroimaging technique (a part of susceptibility-weighted 
imaging, SWI), which uses tissue magnetic susceptibility differences to 
generate a unique contrast, different from that of spin density, T1, T2, and 
T2* (Haacke EM et al, 2009). It measures the phase shifts in gradient-echo 
images. It seems a very sensitive tool to quantify the iron content of the 
brain (Ogg RJ et al, 1999). Furthermore, while R1 (1/T1) and R2 (1/T2) can 
be reversible depending on the water content and other local structural 
changes that can affect relaxation times (in these cases, the effect of iron 
remains invisible), this is not true for R2’ (R2’=R2*-R2) or phase (Haacke 
EM et al, 2005). Tissue containing (paramagnetic) iron exhibits a negative 
phase in complex images compared to immediately adjacent tissue, which 
will have an increased phase. Phase imaging allows a qualitative evaluation 
based on the unique contrast resulting in the images and a quantitative 
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analysis based on the evaluation of local phase differences (measured in 
radians). 
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METHODS 
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Setting, timing and subjects 
 
A total of 25 patients (age 52±10, mean ± SD; 10 males and 15 females) 
(Table 1) were recruited by Sleep Medicine Centre of the Department of 
Neurological Science of Bologna University and they were studied by MR 
in the MR Spectroscopy Unit of the Department of Internal Medicine, 
Aging and Nephrology of Bologna University, from January 2007 to May 
2009. The patients will satisfy the revised criteria of IRLSSG (Allen RP et 
al, 2003). Secondary forms of RLS were excluded by exploring a detailed 
history, by objective evaluation and using laboratory analyses such as 
hemoglobin, iron, ferritin, tranferrin, creatinine, urea and liver enzymes. The 
severity of RLS was assessed on the day of scan using the IRLSSG rating 
scale (Walters AS et al, 2003). 
We have studied also 22 healthy control subjects (age 49±16, mean ± SD; 
14 males and 8 females). 
All control subjects were interviewed by a Sleep Medicine expert in order to 
exclude symptoms suggesting RLS and other neurological disorders. Both 
patients and controls gave written informed consent. Both patients and 
controls not always underwent the complete MR protocol because of time or 
technical problems. So the studied samples differ among the different 
protocols.  
 
MR protocols 
 
Subjects were studied in a 1.5 Tesla GE Signa Horizon LX system equipped 
with a birdcage head radio-frequency coil for signal reception and an 
EchoSpeed gradient system providing a maximum gradient strength of 22 
mT/m and maximum slew rate of 120 mT/m/ms (Figure 1). 
  
1) Structural and microstructural analysis 
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VBM 
Data acquisition. A conventional T1-weighted (T1W) axial volumetric 
image was acquired using the FSPGR sequence TI=600 ms; TE=5.1 ms; 
TR=12.5 ms; 25.6 cm square FOV, 1 mm slice thickness; in-plane 
resolution=256x256.  
Data analysis. Structural data was analysed with FSL-VBM, a voxel-
based morphometry style analysis (Ashburner J and Friston K, 2000) 
carried out with FSL tools (Smith SM et al, 2004) (Figure 2). First, 
structural images were brain-extracted using BET (Smith SM et al, 
2002). Next, tissue-type segmentation was carried out using FAST4 
(Zhang Y et al, 2001). The resulting grey-matter partial volume images 
were then aligned to Montreal Neurological Institute MNI152 standard 
space using the affine registration tool FLIRT (Jenkinson M et al, 2002], 
followed by nonlinear registration using FNIRT 
(www.fmrib.ox.ac.uk/fsl), which uses a b-spline representation of the 
registration warp field (Rueckert D et al, 1999). The resulting images 
were averaged to create a study-specific template, to which the native 
grey matter images were then non-linearly re-registered. The registered 
partial volume images were then modulated (to correct for local 
expansion or contraction) by dividing by the Jacobian of the warp field. 
The modulated segmented images were then smoothed with an isotropic 
Gaussian kernel with a sigma of 3 mm. Finally, voxelwise GLM was 
applied using permutation-based non-parametric testing, correcting for 
multiple comparisons across space, using the program Glm 
(www.fmrib.ox.ac.uk/fsl), applying threshold-free cluster enhancement. 
Sex and age were introduced as covariates. Thresholds for significance 
level were set at P<0.01.  
 
DTI: ROI/histogram analyses and TBSS 
Acquisition. Axial DTI SE-EPI images were obtained (slice thickness = 5 
mm, inter-slice gap = 0 mm) using a single-shot EPI sequence with α = 
90º, TE=89.2 ms; TR=10 s; 32 cm2 FOV, in-plane resolution=192x192, 
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NEX=1, and phase encoding in right-left direction. Six directions-
encoding gradients were applied with gradient strengths corresponding to 
b-values 900 s/mm2. In addition, images without diffusion weighting 
were acquired, corresponding to b = 0 s/mm2 and exhibiting T2-contrast.  
Data preprocessing. Distortions in the DTI-EPI images due to gradient-
induced eddy currents were corrected by slice-wise registration of the DT 
images onto the T2-weighted EPI image using the image registration 
software FLIRT (www.fmrib.ox.ac.uk/fsl). Due to the nature of the 
distortions, the degrees of freedom were restricted to translation, scaling, 
and shearing along the phase encoding direction (Haselgrove et al, 1996). 
Mean diffusivity (MD) and fractional anisotropy (FA) were determined 
pixel-wise using a least-squares fit using the program DTIFIT 
(www.fmrib.ox.ac.uk/fsl). In order to avoid contamination of the MD 
values for grey and white matter by the much higher values of cerebral 
spinal fluid (CSF) during further evaluation, pixels containing CSF were 
masked from the MD map. This was accomplished using the FAST 
algorithm (www.fmrib.ox.ac.uk/fsl) for a two-class segmentation based 
on the corresponding T2-weighted EPI images (Figure 3). 
Manual ROI and histogram analyses. Regions of interest (ROIs) were 
selected manually on T2-weighted EPI images. ROIs were defined to 
include medulla, pons, left and right middle cerebellar peduncle (MCP), 
superior cerebellar peduncle (SCP), dentate nucleus, cerebellar white 
matter, thalamus, caudate, putamen, pallidus, pyramidal tract at the level 
of the posterior limb of internal capsule (PLIC), frontal and parietal white 
matter, optic radiation and corpus callosum (genu and splenium) (Figure 
4-A). Cerebral cortical ROIs were not selected, because substantial 
partial volume effects from subcortical white matter and CSF could not 
be completely avoided. For a global evaluation of brain MD values, 
including cortical areas, histograms of MD were generated for all pixels 
in the sovratentorial and infratentorial compartment (Figure 4-B/C). As 
previously described (Martinelli et al, 2007) infratentorial compartment 
histograms of MD were also generated separately for areas corresponding 
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to brainstem, vermis, and cerebellar hemispheres determined by manual 
segmentation (Figure 4-D). The asymmetry of the MD distribution was 
assessed by finding the 50th percentile values (medians) along with the 
mean (Rizzo et al, 2008) (Figure 4-E). Parametric tests were used as 
Kolmogorov–Smirnov testing showed that means and median values 
were normally distributed. The Student T test was used to evaluate 
differences among two groups and Pearson test to evaluate correlations, 
correcting for multiple comparisons. P values less than 0.05 were 
accepted as statistically significant. 
Tract-based analysis. Voxel-wise statistical analysis of the FA data was 
carried out using TBSS (Tract-Based Spatial Statistics) (Smith SM et al, 
2006), part of FSL (Smith SM et al, 2004). First, FA images were created 
as described in the paragraph 'Data pre-processing'. All subjects' FA data 
were then aligned into a common space using the nonlinear registration 
tool FNIRT (www.fmrib.ox.ac.uk/fsl), which uses a b-spline 
representation of the registration warp field (Rueckert D et al, 1999). 
Next, the mean FA image was created and thinned to create a mean FA 
skeleton which represents the centres of all tracts common to the group. 
Each subject's aligned FA data was then projected onto this skeleton and 
the resulting data fed into voxelwise cross-subject statistics, correcting 
for multiple comparisons, using the program Glm 
(www.fmrib.ox.ac.uk/fsl). Subjects' age and sex were considered 
nuisance variables whose effect was removed from the final group 
comparisons. Thresholds for significant level were set at P<0.01 (Figure 
5). 
 
Automatic segmentations 
Automatic segmentation of the volumetric T1W image was performed 
using FIRST (www.fmrib.ox.ac.uk/fsl) to bilaterally define seven 
subcortical gray matter structures (thalamus, putamen, caudate, pallidus, 
accumbens, hippocampus and amygdala) (Figure 6). In addition, frontal, 
parietal, temporal and occipital lobes, brainstem and cerebellum were 
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defined using the MNI152 template. Within these regions gray matter 
was defined using a three-class segmentation of the T1W images. All 
structures were registered onto the DTI maps in two steps using FLIRT 
(www.fmrib.ox.ac.uk/fsl). White matter partial volume on DTI images 
was masked by registering the MNI FA template onto subjects’ own FA 
map using non-linear registration. Deep gray structures were identified 
by warping the Harvard-Oxford sub-cortical structure atlas (also defined 
in MNI coordinate space). A mask excluding CSF was generated from a 
three-class segmentation of the T2-weighted image volume. ROIs of all 
deep gray and cortical structures was defined in the DTI space by fusing 
registered FIRST, Harvard-Oxford, and CSF and WM exclusion masks 
(Figure 7). For each, volumes and median MD values were calculated. 
Cortical and subcortical volumes were separately corrected for subject 
age and total brain volume, MD values for age only. Statistical analyses 
were performed using SPSS 15.0 for Windows. Parametric tests were 
used as Kolmogorov-Smirnov testing showed that the variables were 
normally distributed. The Student T test was used to evaluate differences 
among two groups. For correlations we used the Pearson test. The 
Bonferroni correction was applied to correct for multiple comparisons. 
Only P values less than 0.05 were accepted as statistically significant. 
 
2) 1H-MRS 
 
Data acquisition. Proton magnetic resonance spectroscopy (1H-MRS) 
study was performed. Single voxel 1H-MRS spectra were acquired using 
the PRESS sequence. The water signal was suppressed by the CHESS 
(Chemical Shift Selective) sequence. A spectrum at short echo-time (TE 
= 35ms; TR = 4 s; number of acquisitions = 128) was acquired in the 
medial region of the thalamus (volume 4.0 to 5.0 cm3) (Figure 8).  
Data analysis. Peak integrals for N-acetyl-aspartate (NAA), creatine-
phosphocreatine (Cr), choline-containing compounds (Cho), and myo-
inositol (mI) were calculated using the operator-independent fitting 
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program LCModel using standard basis sets (Provencher SW, 1993). 
Peak integral values were expressed relative to Cr. The exclusion 
criterion for metabolite evaluation was an LCModel estimated fitting 
error greater than 20%, this being a reliable indicator of poor quality 
spectra. Statistical analyses were performed using SPSS 15.0 for 
Windows. Parametric tests were used as Kolmogorov–Smirnov testing 
showed that the variables were normally distributed. The Student T test 
was used to evaluate differences among two groups. For correlations we 
used the Pearson test. For all analyses, only P values less than 0.05 were 
accepted as statistically significant. 
 
3) Phase imaging 
 
Data acquisition. Anatomical imaging was performed by a T2-weighted 
(T2W) FSE sequence in an axial oblique plane, using acquisition 
parameters: α=90º; echo time (TE): 107 ms; repetition time (TR): 5080 
ms; square FOV: 24 cm; acquisition matrix 320×256; reconstructed in-
plane resolution: 0.938 mm; slice thickness; 4 mm w/o gap. # slices 
variable to cover whole head. NEX: 2. Phase-sensitized images were 
acquired using a gradient echo sequence, and preserving both real and 
imaginary channels. Slice locations matched those of the anatomical 
scan, excluding slices above the central corpus callosum, and below the 
dentate nucleus. Acquisition parameters: TE/TR: 40/60 ms; acquisition 
matrix 512×256; reconstructed in-plane resolution: 0.938 mm; NEX 2; 
bandwidth 15.6 kHz; maximum acquisition time 7’06”.  
Data analysis. Following the published method (Ogg RJ et al, 1999) data 
were high pass filtered by multiplication with a filter function in k-space, 
using tools provided by FSL (FMRIB; U Oxford) and AFNI (NIMH, 
NIH; Bethesda MD), and a phase map prepared using the filtered data. 
T2W data were registered onto the gradient echo data using FLIRT (FSL) 
(Figure 9). Whole brain regions of interest were selected automatically 
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by thresholding T2W data, and excluding pixels whose local filtered 
phase dispersion exceeded a second threshold (indicating low 
signal:noise) (Figure 10). Regions of interest were selected in two ways: 
structures known to accumulate iron (dentate and red nucleus, substantia 
nigra, basal ganglia) were manually segmented using both phase maps 
and T2W images (Figure 11). For whole brain ROIs, the 10th, 50th and 
90th percentile of the filtered phase histogram were calculated, while for 
local ROIs, 25th and 50th percentiles only, as these contained mainly 
negative phase. For each percentile score, patients and control groups 
were compared using the Mann-Whitney U test, and correlation with 
demographic and clinical parameters used the Spearman test. The 
Bonferroni correction was applied to correct for multiple comparisons. 
Statistical analyses will be performed using with SPSS 15.0 for 
Windows, assuming a significant P-value <0.05. 
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RESULTS 
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Structural and microstructural analysis 
 
Subjects 
22 patients (age 50±9, mean±SD; 7 males and 15 females) and 22 healthy 
controls (age 49±16, mean ± SD; 14 males and 8 females) were studied. 
Mean values and standard deviations of age at onset, disease duration and 
IRLSSG score in RLS patients were 41±12 years, 9±8 years and 22±7 
respectively. 14 patients never took therapy and 8 patients receiving 
dopaminergic therapy were free from drugs from at least 2 weeks before 
scan. 8 patients had a family history of RLS (Table 2). 
 
MR data 
VBM 
No significant difference in volume or density was found in any brain 
area. The lack of differences still remains when age and sex were 
introduced as a cofactor (Figure 12). 
DTI 
For all ROIs selected MD and FA values in RLS patients were not 
significantly different from controls (Table 3). Similarly, the histograms 
of MD and FA in the whole sovratentorial and infratentorial 
compartment and in the brainstem, vermis, and cerebellar hemispheres 
singly were virtually identical for the two groups and no significant 
differences were observed at level of median MD values (Table 3). 
TBSS group comparison revealed no difference in MD and FA of any 
brain area between two groups. The lack of differences still remains 
when age and sex were introduced as a cofactor (Figure 13). 
Automatic segmentation 
No significant difference in volume or MD values was disclosed in any 
segmented structures. (Table 4) 
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1H-MRS 
 
Subjects 
25 patients (age 52±10, mean±SD; 10 males and 15 females) and 18 
healthy controls (age 51±16, mean ± SD; 11 males and 7 females) were 
studied  Mean values and standard deviations of age at onset, disease 
duration and IRLSSG score in RLS patients were 43±13 years, 9±8 years 
and 22±7 respectively. 16 patients never took therapy and 9 patients 
receiving dopaminergic therapy were free from drugs from at least 2 
weeks before scan. 9 patients had a family history of RLS (Table 5). 
 
MR data 
The NAA/Cr and Cho/Cr ratios were significantly lower in the medial 
thalamus of RLS patients compared with the healthy controls (Table 6, 
Figures 14 and 15). We did not detect statistical differences in the other 
ratios. The reduction of the NAA/Cr and Cho/Cr ratios in the thalamus of 
the patients did not correlate with the clinical variables considered (age, 
age at onset, disease duration, IRLSSG rating scale for symptoms 
severity). 
 
Phase imaging 
 
Subjects 
11 patients (age 54±11, mean±SD; 2 males and 9 females) and 11 healthy 
controls (age 51±18, mean ± SD; 6 males and 5 females) were studied  
Mean values and standard deviations of age at onset, disease duration and 
IRLSSG score in RLS patients were 48±11 years, 6±3 years and 21±9 
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respectively. 8 patients never took therapy and 3 patients receiving 
dopaminergic therapy were free from drugs from at least 2 weeks before 
scan. 5 patients had a family history of RLS (Table 7). 
 
MR data 
In the whole brain analysis, RLS patients showed lower phase dispersion, 
characterized by 10th and 90th percentile radians values of significantly 
smaller magnitude than in controls (respectively p=0.01 and p=0.02), 
while the median was no different (Table 8 and Figure 16). In the 
localized ROIs, differences were not significant although there was a 
trend of more negative radians values, prevalently in red nucleus and 
substantia nigra (Table 8). The 10th percentile of whole brain phase in 
RLS patients correlated with disease duration (r=0.60, p=0.04) (Figure 
17), but not with IRLSSG rating scale or other clinical/demographic 
parameters. 
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DISCUSSION 
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In this study we have used advanced MR techniques to investigate various 
aspects of RLS pathophysiology. Firstly, we used a multimodal approach to 
evaluate the possible presence of structural and/or microstructural 
abnormalities in terms of volume and/or DTI parameters alterations using 
ROI/istogram analysis, VBM, TBSS and automatic segmentations of brain 
structures. Neither volume or MD or  FA pathological changes were found 
in any brain structures of RLS patients. Regarding four previous VBM 
studies (Etgen T et al, 2005; Unrath A et al, 2007; Hornyak M et al, 2007; 
Celle S et al, 2009) our data are in accord only with the most recent one 
which found a lack of specific grey matter alterations in RLS patients (Celle 
S et al, 2009). Discrepancies with other studies might on the one hand be 
explained by methodological differences, since the first study, detecting 
increasing pulvinar grey matter, was performed by use of the classical VBM 
technique (Etgen T et al, 2005). All other studies, including our, used the 
optimised VBM protocol (Good CD et al, 2001). Differently from previous 
studies, our study used the software FSL-VBM instead of SPM, although 
the two software packages seem to give similar results (Battaglini M et al, 
2009). For example Cell et al found results very similar to ours, using SPM. 
Another important note regarding the first two VBM works is that in neither 
study did the results survive a correction for multiple comparisons (Etgen T 
et al, 2005; Unrath A et al, 2007). 
Methodological differences are also present between our and a previous DTI 
analysis (Unrath A et al, 2008), which disclosed an FA reduction in the 
sensori-motor cortical regions not confirmed in our study. Indeed, Unrath et 
al used standard registration algorithms that didn’t give a satisfactory 
solution to the question of how to align FA images from multiple subjects 
with an arbitrariness of the choice of spatial smoothing extent. We have 
chosen to used TBSS, which resolves these issues by using the ‘‘mean FA 
skeleton’’ approach (Smith SM et al, 2006 and 2007). Lack of any MD or 
FA abnormalities was confirmed by the ROI and histogram analysis. 
Furthermore for the first time in RLS patients we evaluated volume and DTI 
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parameters at level of cortical and subcortical areas using automatic 
segmentation and again no pathological changes were present. 
On the other hand, these technical aspects alone might not be sufficient to 
explain the different results among different studies. The heterogeneity in 
terms of size and clinical features of the studied samples could be a 
considerable factor. The presence of medical treatment, such as 
dopaminergic agents, is an important issue, because these are known to 
affect the morphology of cerebral structures (Corson PW et al, 1999). In 
some studies (Etgen T et al, 2005; Unrath A et al, 2007 and 2008) almost all 
the patients were on treatment, but not in all cases (Hornyak M et al, 2007; 
Celle S et al, 2009).  In our sample most patients (n=16) never took therapy. 
In the remaining 9 patients treated with dopaminergic drugs, treatment was 
stopped for at least 2 weeks before scan. Other possible differences among 
the studies would regard the severity of symptoms, the percentage of family 
history, and the co-occurrence of other sleep disorders. Finally the possible 
heterogeneity of RLS itself might be reflected in the different results. 
Overall our VBM and DTI data argue against clear 
structural/microstructural abnormalities in the brain of patients with 
idiopathic RLS. 
The second part of our study focused on thalamic involvement. Using 1H-
MRS we detected metabolic changes in the medial region of the thalamus. 
This region is a part of the medial nociceptive system. This system projects 
through medial and intralaminar nuclei of the thalamus to several cortical 
and limbic regions: frontal and insular cortices and anterior cingulate gyrus. 
It is thought to mediate affective-motivational aspects of pain such as 
emotional reactions, arousal and attention to the stimulus, as well as the 
drive to escape from the noxious stimuli (Treede RD et al, 1999; Price DD, 
2000). An activation of these brain structures during pain perception has 
been confirmed by PET and fMRI studies (Apkarian AV et al, 2005).  
H2[15O] PET (San Pedro EC et al, 1998) and fMRI (Bucher SF et al, 1997; 
Astrakas LG et al, 2008) found similar brain activation in RLS patients. A 
PET study with [11C]diprenorphine, a non-selective opioid receptor 
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radioligand, disclosed regional negative correlations between ligand binding 
and RLS severity in areas serving the medial pain system (medial thalamus, 
amygdala, caudate nucleus, anterior cingulate gyrus, insular cortex and 
orbitofrontal cortex) (von Spiczak S et al, 2005). Another PET study which 
used the high-affinity D2-receptors radioligands [11C]FLB 457 reported a 
higher thalamic binding potential in RLS patients than in controls, at the 
level of the medial and posterior portions, other than at the level of limbic 
and associative part of striatum, anterior cingulate cortex and insulae, 
suggesting again an involvement of the medial pain system (Cervenka S et 
al, 2006). Neurophysiological studies have shown an impairment of pain 
and temperature perception in idiopathic RLS, with an absence of peripheral 
nerve fibre damage suggesting a functional impairment of central 
somatosensory processing (Stiasny-Kolster K et al, 2004; Schattschneider J 
et al, 2004; Tyvaert L et al, 2009b). Interestingly one study has disclosed 
increased ratings of pin-prick pain in untreated RLS patients indicating 
static hyperalgesia that was more pronounced in the lower limb and reversed 
by long-term dopaminergic treatment (Stiasny-Kolster K et al, 2004). 
Our MR spectroscopic data confirm a thalamic involvement in RLS 
patients, presumably not due to degenerative changes given that none were 
detected by VBM and DTI studies (see above). This abnormality could be 
an epiphenomenon in the pathophysiology of RLS, in terms of metabolic 
dysfunction secondary to discomfort perception. But it is also possible that 
the involvement of the medial portion of the thalamus could have a primary 
role, because its function is modulated by dopaminergic afferents. Indeed, 
an extensive mesothalamic and nigrothalamic system originates as 
collaterals from A8-A9-A10 neurons (Freeman A et al, 2001). Thus, DA 
axons directly innervate thalamic components of several parallel, 
functionally unique, basal ganglia-thalamocortical loops as follows: motor 
(ventrolateral; VL), ‘prefrontal’ (parvocellular ventroanterior; VApc), and 
‘limbic’ (mediodorsal; MD) in non-human primates and humans (Rye DB, 
2004).   
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From this point of view the thalamic metabolic alteration which we have 
found may reflect an impairment of medial pain system secondary to a 
dopaminergic dysfunction and leading to a abnormal affective-motivational 
sensory-motor processing of the sensory inputs. This could also happen in 
parallel with a dysfunction of other dopaminergic pathways such as the 
diencephalospinal pathway projecting from A11 area to spinal cord in a 
contest of a multilevel demodulation of pain stimuli perception.    
The third part of our study investigated the brain iron content of RLS 
patients and disclosed a global brain iron reduction in these patients 
compared to healthy subjects of a similar age. We used a quantitative 
evaluation of the phase maps obtained by a SWI protocol. Paramagnetic 
tissue causes a dipolar effect and iron presence strictly affects the 
paramagnetic properties of the tissues (Ogg RJ et la, 1999). In our work 
alterations were seen in both the 10th and the 90th percentile of the whole 
brain histogram where the extremes of image phase variation were reduced, 
due to reduced paramagnetic tissue content in RLS subjects. This is 
consistent with a lower iron content compared to normal brains. This 
alteration correlated with disease duration. These data are in agreement with 
the previous MRI studies that found increased T2, T2* and T2' (and reduced 
R2, R2* and R2') in different brain structures including substantia nigra, 
thalamus and caudate (Allen RP et al, 2001; Earley CJ et al, 2006; Astrakas 
LG et al, 2008; Godau J et al, 2008). Variability in these results points 
toward a non localized reduced iron content but most probably a diffuse 
lowering. Indeed despite the small sample size we found an alteration at the 
whole brain analysis, which appears to be more sensitive than the local ROI 
analysis where we did not detect significant differences but only a trend. 
Alterations of iron regulatory proteins such as ferritin, divalent metal 
transporter 1, ferroportin, transferrin, transferrin receptor, pro-hepcidin and 
hepcidin detected in neuromelanin cells and CSF from brains of patients 
(Clardy SL et al, 2006b; Connor JR et al, 2003 and 2004) indicate a basic 
alteration of brain iron homeostasis, probably affecting the control of iron 
movement between CSF and brain and between extracellular and 
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intracellular compartments. Iron deficiency should impair the function of 
some cerebral systems more than others, notably the dopaminergic system, 
because of the strong connection between dopamine and iron (Allen RP, 
2004; Allen RP and Earley CJ, 2007). Under this hypothesis, an 
involvement of all the various  dopaminergic pathways could be present at a 
subclinical level, but only that of networks implicated in sensori-motor 
integration and pain processing would be clearly evident at clinical level, 
either because of a further major susceptibility to iron deficiency in neurons 
in this network, or because of differences in the threshold of perceptibility 
of the dysfunction (sensory dysfunction through pain system rather than 
motor impairment through nigrostriatal system for example). 
A methodological consideration coming from our study is that the histogram 
analysis of the phase maps is a very sensitive tool to evaluate brain iron 
content and is also far less operator dependent. This suggests that this 
imaging protocol may also be useful in all types of neurological disease 
characterized by a pathological increase of iron accumulation, primary 
(neurodegeneration with brain iron accumulation) or secondary 
(neurodegenerative diseases), as a biomarker of disease progression and for 
assessment of pharmacological interventions with chelating drugs. 
In summary, putting together the results of all the different MR protocols 
adopted in this study, we can support a pathophysiological model of RLS 
which is consistent with low brain iron content in the brains of these 
patients. The iron deficiency may lead to a functional impairment, in the 
absence of structural and/or microstructural abnormalities. Via 
dopaminergic dysfunction, this functional impairment affects the central 
mechanisms of sensori-motor integration and pain processing involving a 
number of brain structures including the medial thalamus (part of medial 
pain system). 
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TABLES AND FIGURES 
 42 
Table 1. Patients recruited for MR studies. All patients performed the 1H-
MRS study. *=performed structural-microstructural study. #=performed 
phase imaging study. 
 
DA drugs = dopaminergic drugs; IRLSSGRS = International Restless Legs Syndrome 
Study Group Rating Scale 
 
Patients Age (y) Sex 
Age at 
onset (y) 
Disease 
length (y) 
Therapy 
Family 
history 
IRLSSGRS 
score 
1* 48 M 45 3 / No 22 
2* 49 F 39 10 / No 21 
3* 46 M 15 31 DA drugs Yes 26 
4* 43 F 40 3 / No 24 
5* 43 F 35 8 / No 26 
6* 55 F 48 7 / No 23 
7* 43 F 19 24 DA drugs No 25 
8* 56 M 40 16 DA drugs Yes 21 
9* 31 M 30 1 / Yes 22 
10* 50 F 24 26 DA drugs No 26 
11 66 M 59 7 DA drugs Yes 28 
12* 50 M 49 1 / No 8 
13* 58 M 56 2 DA drugs No 24 
14* 67 M 57 10 / No 20 
15*# 65 F 58 7 / Yes 24 
16*# 50 F 40 10 DA drugs No 24 
17# 58 M 54 4 / No 22 
18# 69 F 66 3 / No 10 
19*# 56 M 51 5 DA drugs No 30 
20*# 48 F 38 10 / No 28 
21*# 49 F 45 4 / Yes 9 
22*# 45 F 40 5 / No 12 
23*# 31 F 25 6 / Yes 11 
24*# 62 F 50 12 DA drugs Yes 35 
25*# 61 F 57 4 / Yes 21 
Mean 52  43 9 9/16 9/16 22 
SD 10  13 8 / / 7 
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Figure 1. 1.5 Tesla GE Signa Horizon LX system equipped with a birdcage 
head radio-frequency coil for signal reception. 
 
 
 
 
 
Figure 2. Schematic illustration of methodological steps of FSL-VBM 
(from www.fmrib.ox.ac.uk/fsl). A: Original T1-weighted volumetric 
images; B: Segmented grey matter partial volume; C: spatially smoothed 
grey matter partial volume; D: Regions of significant group difference in 
GM volume (colour) superimposed on template T1-weighted image. 
 
A B C 
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Figure 3. Schematic illustration of preprocessing of DTI images for FA/MD 
analysis. A: DTI image. B: T2W image. C: MD map. D: First eigenvector 
map weighted by FA. 
 
 
 
 
Figure 4. A: Example of manual segmentation of ROIs. B-D: manual 
segmentation of whole left and right hemispheres (B), whole infratentorial 
compartment (C) and of the areas corresponding to brainstem, vermis, and 
cerebellar hemispheres separately for histogram analysis (D). E: example of 
cerebral hemisphere histograms in a healthy control. 
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Figure 5. Schematic illustration of methodological steps of TBSS (from 
www.fmrib.ox.ac.uk/fsl).  
 
 
 
 
Figure 6. Example of three dimensional projection of automatically 
generated subcortical structures (colour) onto T1-weighted volumetric 
image (greyscale). 
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Figure 7. Data pipeline to create automatic ROIs. 
 
 
 
 
 
 
Figure 8. Localization of medial thalamic VOI (volume of interest) for 1H-
MRS study (A) and example of spectrum (B) in a control subject. NAA = 
N-acetyl-aspartate; Cr = creatine-phosphocreatine; Cho = choline-
containing compounds; mI = myo-inositol. 
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Figure 9. Schematic illustration of preprocessing of phase images. A-B: real 
and imaginary images; C-D: Low pass filtered images; E: phase map; F-H: 
details of iron-rich structures (F: basal ganglia, G: substantia nigra and red 
necluei, H: dentate nuclei). 
 
 
 
 
 
Figure 10. Whole brain ROI (A) and derived phase histogram from a 
healthy control (B). 
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Figure 11. Manual segmentation of ROIs at level of iron-rich structures (A: 
basal ganglia, B: substantia nigra and red necluei, C: dentate nuclei). 
 
 
 
 
 
 
 
 
Table 2. Clinical data of the RLS patients and controls of the 
structural/microstructural study. 
Subjects 
(N) 
Age 
(years) 
Sex 
(M/F) 
Age at 
onset 
(years) 
Disease 
duration 
(years) 
IRLSSG 
score 
Therapy 
(DA 
drugs) 
(N) 
Positive 
family 
history 
(N) 
RLS 
patients 
(22)  
50±9 7/15 41±12 9±8 22±7 8 (36%) 8 (36%) 
Healthy 
controls 
(22) 
49±16 14/8 / / / / / 
M, male; F, female; DA drugs = Dopaminergic drugs; IRLSSGRS = International Restless 
Legs Syndrome Study Group Rating Scale. All data are given as mean ± SD.  
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Figure 12. VBM analysis disclosed no differences between two groups. 
Thresholds for significance level were set at P<0.01 after correction for 
multiple comparisons across space, and applying threshold-free cluster 
enhancement. 
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Table 3. MD and FA values for control and RLS groups by ROI and 
histogram analysis of DTI images. 
 
*Student T test (a P-value of <0.05 after correction for multiple comparisons was 
considered to be significant). MD= Mean diffusivity; FA= Fractional anisotropy. # = Mean 
of the left and right values. ## = Mean of the genu and splenium. All data are given as mean 
± SD. 
 
 
  
 
 
 
 
 
 
 
 
 
ROIs 
MD (x10-3 mm2/s) FA  P* 
 Controls RLS patients Controls RLS patients 
Mean values 
Medulla 0.84±0.07 0.86±0.08 0.46±0.12 0.44±0.10 n.s. 
Dentate nucleus# 0.69±0.06 0.74±0.06 0.34±0.07 0.31±0.07 n.s. 
Pons 0.87±0.06 0.91±0.05 0.43±0.07 0.47±0.08 n.s. 
Middle cerebellar peduncle# 0.74±0.06 0.78±0.05 0.60±0.04 0.57±0.07 n.s. 
Superior cerebellar peduncle# 0.69±0.03 0.69±0.05 0.48±0.10 0.43±0.10 n.s. 
Cerebellar white matter# 0.81±0.04 0.77±0.06 0.67±0.07 0.69±0.06 n.s. 
Posterior limb of internal capsule# 0.69±0.03 0.71±0.03 0.68±0.04 0.52±0.07 n.s. 
Thalamus# 0.78±0.02 0.78±0.05 0.32±0.02 0.70±0.04 n.s. 
Putamen# 0.75±0.02 0.75±0.02 0.24±0.03 0.33±0.03 n.s. 
Globus pallidus# 0.73±0.03 0.75±0.04 0.38±0.04 0.23±0.03 n.s. 
Caudate# 0.79±0.03 0.80±0.03 0.24±0.03 0.38±0.04 n.s. 
Parietal white matter# 0.85±0.07 0.84±0.06 0.39±0.07 0.22±0.02 n.s. 
Frontal white matter# 0.78±0-04 0.76±0.03 0.29±0.04 0.41±0.05 n.s. 
Corpus callosum## 0.82±0-05 0.83±0.04 0.76±0.03 0.29±0.04 n.s. 
Optic radiation# 0.83±0.04 0.83±0.03 0.55±0.04 0.76±0.05 n.s. 
Median values 
Sovratentorial compartment 0.89±0.05 0.86±0.03 0.23±0.02 0.24±0.02 n.s. 
Infratentorial compartment 0.87±0.05 0.87±0.05 0.29±0.04 0.31±0.04 n.s. 
Brainstem 0.90±0.05 0.87±0.05 0.44±0.04 0.45±0.02 n.s. 
Vermis 0.98±0.11 0.96±0.07 0.23±0.03 0.24±0.04 n.s. 
Cerebellar hemispheres 0.81±0.03 0.83±0.05 0.29±0.05 0.30±0.05 n.s. 
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Figure 13. TBSS analysis of DTI images disclosed no differences between 
two groups. Thresholds for significance level were set at P<0.01 after 
correction for multiple comparisons across space, and applying threshold-
free cluster enhancement. 
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Table 4. MD values and volumes for control and RLS groups selected by 
automatic ROI segmentation. 
 
Volume (mm3) 
 Controls RLS patients P* 
 Mean ±SD Mean ±SD 
Occipital lobe# 101259 12651 98645 9738 n.s. 
Parietal lobe# 149318 15213 148619 14795 n.s. 
Temporal lobe# 141164 11859 140741 15285 n.s. 
Frontal lobe# 239190 26608 239435 23835 n.s. 
Caudate# 7199 708 6712 819 n.s. 
Pallidus# 3572 447 3450 391 n.s. 
Putamen# 9680 1315 9441 926 n.s. 
Thalamus# 15572 1829 14862 1333 n.s. 
Accumbens# 1033 185 1101 156 n.s. 
Hippocampus# 7822 1077 7633 518 n.s. 
Amygdala# 2775 389 2630 474 n.s. 
Brainstem 23566 2804 21650 9455 n.s. 
Cerebellum 110160 11203 104524 10450 n.s. 
MD (x10-3 mm2/s) 
 Controls RLS patients P* 
 Mean ±SD Mean ±SD 
Occipital lobe# 0,84 0,04 0,81 0,03 n.s. 
Parietal lobe# 0,79 0,04 0,77 0,03 n.s. 
Temporal lobe# 0,85 0,03 0,83 0,02 n.s. 
Frontal lobe# 0,80 0,04 0,79 0,02 n.s. 
Caudate# 0,77 0,02 0,80 0,02 n.s. 
Pallidus# 0,77 0,06 0,76 0,02 n.s. 
Putamen# 0,75 0,02 0,74 0,02 n.s. 
Thalamus# 0,79 0,05 0,78 0,04 n.s. 
Accumbens# 0,80 0,05 0,80 0,03 n.s. 
Hippocampus# 0,92 0,04 0,91 0,04 n.s. 
Amygdala# 0,86 0,05 0,87 0,04 n.s. 
Brainstem 0,83 0,03 0,85 0,05 n.s. 
Cerebellum 0,79 0,03 0,80 0,04 n.s. 
*Student T test (a P-value of <0.05 after correction for multiple comparisons was 
considered to be significant). MD= mean diffusivity. # = Mean of the left and right values. 
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Table 5. Clinical data of the RLS patients and controls of the 1H-MRS 
study. 
Subjects 
(N) 
Age 
(years) 
Sex 
(M/F) 
Age at 
onset 
(years) 
Disease 
duration 
(years) 
IRLSSG 
score 
Therapy 
(DA 
drugs) 
(N) 
Positive 
family 
history 
(N) 
RLS 
patients 
(25)  
52±10 10/15 43±13 9±8 22±7 9 (36%) 9 (36%) 
Healthy 
controls 
(18) 
51±16 11/7 / / / / / 
M, male; F, female; DA drugs = dopaminergic drugs; IRLSSGRS = International Restless 
Legs Syndrome Study Group Rating Scale. All data are given as mean ± SD.  
 
 
 
 
 
 
 
 
 
 
 
Table 6. 1H-MRS results in RLS patients and healthy controls. 
 
Ratios 
 Controls RLS patients P* 
 Mean ±SD Mean ±SD 
NAA/Cr 1.39 0.11 1.24 0.16 <0.01 
Cho/Cr 0.31 0.04 0.29 0.03 <0.05 
mI/Cr 0.83 0.17 0.78 0.13 n.s. 
*Student T test (a P-value of <0.05 was considered to be significant). NAA = N-acetyl-
aspartate; Cr = creatine-phosphocreatine; Cho = choline-containing compounds; mI = myo-
inositol. 
 
 
 
 
 
 
 
 54 
Figure 14. Examples of medial thalami spectra in one RLS patient and one 
control. NAA = N-acetyl-aspartate; Cr = creatine-phosphocreatine; Cho = 
choline-containing compounds; mI = myo-inositol. 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Box-plots of 1H-MRS data of RLS patients and controls (A: 
NAA/Cr; B: Cho/Cr). 
 
 
**=P<0.01; *=P<0.05 
 
 
** 
* 
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Table 7. Clinical data of the RLS patients and controls of the phase imaging 
study. 
 
Subjects 
(N) 
Age 
(years) 
Sex 
(M/F) 
Age at 
onset 
(years) 
Disease 
duration 
(years) 
IRLSSG 
score 
Therapy 
(DA 
drugs) 
(N) 
Positive 
family 
history 
(N) 
RLS 
patients 
(11)  
54±11 2/9 48±11 6±3 21±9 3 (27%) 5 (46%) 
Healthy 
controls 
(11) 
51±18 6/5 / / / / / 
M, male; F, female; DA drugs = dopaminergic drugs; IRLSSGRS = International Restless 
Legs Syndrome Study Group Rating Scale. All data are given as mean ± SD.  
 
 
 
 
 
 
Table 8. Phase image analysis of RLS patients and controls. 
 
Phase (radians) 
 Controls RLS patients P* 
 Mean ±SD Mean ±SD 
Dentate nucleus 25th# -0,172 0,033 -0,165 0,024 n.s. 
Dentate nucleus 50th# -0,060 0,027 -0,062 0,022 n.s. 
Red nucleus 25th# -0,265 0,055 -0,234 0,056 n.s. 
Red nucleus 50th# -0,141 0,039 -0,132 0,043 n.s. 
Substantia nigra 25th# -0,287 0,046 -0,243 0,077 n.s. 
Substantia nigra 50th# -0,138 0,042 -0,119 0,072 n.s. 
Basal ganglia 25th# -0,205 0,026 -0,203 0,028 n.s. 
Basal ganglia 50th# -0,075 0,015 -0,081 0,016 n.s. 
Histogram of whole brain 
10th percentile -0,220 0,007 -0,208 0,010 0.01 
50th percentile 0,000 0,003 0,002 0,001 n.s. 
90th percentile 0,214 0,009 0,200 0,009 0.02 
*Mann–Whitney U test (a P value of < 0.05 after correction for multiple comparisons was 
considered to be significant). # = Mean of the left and right values. 
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Figure 16. Box-plots of 10th, 50th and 90th values from histograms of phase 
in RLS patients and controls. 
 
 
**=P<0.05 
 
 
 
 
 
Figure 17. Correlation between 10th values from histograms of phase in 
RLS patients and disease duration (Spearman rank test). 
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